SCHEMBL560707

SCHEMBL560707

CC(=O)Nc1ccc(Oc2cnc(N)c(-c3nc4ccc(C)cc4[nH]3)n2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.53
HPGD P15428 5/20 0.53
THRB P10828 1/20 0.51
HTT P42858 2/20 0.49
HPSE Q9Y251 1/20 0.49
ATR Q13535 6/20 0.48
CHEK2 O96017 1/20 0.47
KDM4E B2RXH2 4/20 0.45
MEN1 O00255 3/20 0.45
KMT2A Q03164 3/20 0.45
TP53 P04637 3/20 0.45
HSD17B10 Q99714 3/20 0.45
TDP1 Q9NUW8 1/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
RECQL P46063 1/20 0.45
MMP2 P08253 1/20 0.45
MMP9 P14780 1/20 0.45
MMP8 P22894 1/20 0.45
MMP13 P45452 1/20 0.45
SLC2A1 P11166 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL559824 0.86 ATR (0.54) ATRCHEK2MMP2MMP9MMP8
SCHEMBL561073 0.86 CHEK2 (0.54) ATRCHEK2
SCHEMBL559946 0.85 ATR (0.51) ALDH1A1HPGDHPSEATRCHEK2
SCHEMBL561015 0.84 ATR (0.52) ALDH1A1HPGDHTTATRCHEK2
SCHEMBL560755 0.83 ATR (0.51) ALDH1A1HPGDHTTHPSEATR
SCHEMBL560098 0.83 ATR (0.53) ALDH1A1HPGDHTTATRCHEK2
SCHEMBL10165965 0.80 ATR (0.52) ALDH1A1HPGDHTTATRCHEK2
SCHEMBL560062 0.80 ATR (0.49) ALDH1A1HPGDATRCHEK2KDM4E
SCHEMBL560151 0.80 KMT2A (0.56) ALDH1A1HPGDHTTATRKDM4E
SCHEMBL560486 0.79 ATR (0.51) ALDH1A1HPGDTHRBHPSEATR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8962631-B2 Compounds useful as inhibitors of ATR kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2015-02-24 US disclosed
US-8962631-B2 Compounds useful as inhibitors of ATR kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2015-02-24 US disclosed
US-8962631-B2 Compounds useful as inhibitors of ATR kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2015-02-24 US disclosed
EP-2569289-A1 PYRAZINES USEFUL AS INHIBITORS OF ATR KINASE Vertex Pharmaceuticals Incorporated (US) 2013-03-20 EP disclosed
US-20120035407-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-02-09 US disclosed
US-20120035407-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-02-09 US disclosed
US-20120035407-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-02-09 US disclosed
WO-2011143419-A1 PYRAZINES USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-11-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120035407-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE ATR, CHEK1, CHEK2 ALDH1A1 4062/4885HPGD 3072/4885THRB 1556/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.